Hematologic and hemostatic disorders are common causes of morbidity, mortality and hospital admissions. The NHLBI supported Transfusion Medicine Hemostasis Clinical Trials Network (TMH-CTN) was developed 4 years ago to conceive, develop and perform network based clinical trials addressing important questions in transfusion medicine and hemostasis. Case Western Reserve University/University Hospitals of Cleveland has been an active member of this network, and under the direction of the applicant played an important role in the mission of the TMH-CTN. The purpose of this application is to describe the activities of the applicant and institution, and to define the direction of the TMH-CTN network over the next funding period, if awarded. The mission of the network over this period is to continue to evaluate promising new therapies for hemostatic disorders such as immune thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP), as well as new blood products such as platelets and platelet substitutes, thrombopoetin analogues and cytokines. Other disorders including hemophilia, heparin-induced thrombocytopenia, and autoimmune hemolytic anemia will also provide substrates for further investigation. Through regular participation in disease-oriented subgroups, the TMH-CTN steering committee, training of institutional participants in disorders relevant to the network, and oversight of ongoing clinical trials, the applicant hopes to continue to make contributions to the TMH-CTN through by devoting personal energy and insight as well as harnessing the clinical resources of Case Western Reserve University, University Hospitals of Cleveland and Rainbow Babies and Children's Hospital to successfully perform network based trials focused on important disorders relevant to the areas of hemostasis and transfusion medicine over the next years.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL072033-08
Application #
8138402
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Mondoro, Traci
Project Start
2002-09-30
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2012
Total Cost
$28,260
Indirect Cost
$10,260
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Uhl, Lynne; Assmann, Susan F; Hamza, Taye H et al. (2017) Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood 130:1247-1258
Kaufman, Richard M; Assmann, Susan F; Triulzi, Darrell J et al. (2015) Transfusion-related adverse events in the Platelet Dose study. Transfusion 55:144-53
Chaturvedi, Shruti; Sidana, Surbhi; Elson, Paul et al. (2014) Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS One 9:e94048
Leissinger, C; Josephson, C D; Granger, S et al. (2014) Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost 112:445-58
Chaturvedi, Shruti; Carcioppolo, Desiree; Zhang, Li et al. (2013) Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. Am J Hematol 88:560-5
Kistangari, Gaurav; McCrae, Keith R (2013) Immune thrombocytopenia. Hematol Oncol Clin North Am 27:495-520
Despotovic, Jenny M; Lambert, Michele P; Herman, Jay H et al. (2012) RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion 52:1126-36; quiz 1125
Josephson, Cassandra D; Granger, Suzanne; Assmann, Susan F et al. (2012) Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 120:748-60
Triulzi, Darrell J; Assmann, Susan F; Strauss, Ronald G et al. (2012) The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 119:5553-62
McCrae, Keith (2011) Immune thrombocytopenia: no longer 'idiopathic'. Cleve Clin J Med 78:358-73

Showing the most recent 10 out of 14 publications